DraftPremera BluecrossPolicy N/A

Pharmacologic Treatment of Neuropathy, Fibromyalgia, and Seizure Disorders

This policy describes pharmacy and medical benefit management and medical necessity criteria for specific medications used to treat neuropathic pain, fibromyalgia, restless legs syndrome, seizure disorders, and related indications; it applies to providers seeking prior authorization for the listed agents.

Policy Summary

PayerPremera Bluecross

PolicyPharmacologic Treatment of Neuropathy, Fibromyalgia, and Seizure Disorders

Policy CodePolicy N/A

Change TypeCoverage criteria added and prior authorization updates

Effective DateNov. 1, 2025 Oct. 14, 2025 N/A

Next Review DateN/A

Key ActionSubmit prior authorization with chart notes/medical records documenting required trials of listed generic medications and intolerance or inadequate response when seeking coverage.

SourceLink

POLICY UPDATE CHANGES

Added coverage criteria for Qutenza (capsaicin) for treatment of postherpetic neuralgia and diabetic peripheral neuropathy.

Removed prior authorization requirement for generic pregabalin and generic pregabalin extended-release.

Included generic SNRI trial as a qualifier for coverage.

Clarified that medications listed are subject to the product's FDA dosage and administration prescribing information.

Added HCPCS code J7336 to the policy.

Added coverage for Neurontin (gabapentin) for neuropathic pain and seizure disorders (effective 09/01/25).

Changed terminology from 'patient' to 'individual' for standardization.

Jul 4, 2024Effective date for Qutenza coverage criteria

J7336HCPCS code listed for Qutenza

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

12 monthsMaximum non-formulary authorization

multiple RCTsTrials showing duloxetine efficacy

2016-2023Annual literature review entries

Coverage and Medical Necessity Criteria

Agent-specific medical necessity criteria (examples)

Covered when the drug-specific criteria below are met (examples shown for several agents).

Gabapentin extended-release / Gralise: Managed under pharmacy benefit; may be considered medically necessary for neuropathic pain when ALL are met: the individual is aged 18 years or older AND has tried and had an inadequate response or intolerance to generic gabapentin AND has tried and had an inadequate response or intolerance to one of: a tricyclic antidepressant (e.g., amitriptyline) or an SNRI (e.g., duloxetine, venlafaxine).age >=18

documentation required

Gabarone (gabapentin): Managed under pharmacy benefit; may be considered medically necessary for the treatment of neuropathic pain when ALL are met: the individual is aged 18 years or older AND has tried and had an inadequate response or intolerance to generic gabapentin AND has tried and had an inadequate response or intolerance to one of: a tricyclic antidepressant (e.g., amitriptyline) or an SNRI (e.g., duloxetine, venlafaxine).age >=18

Also may be used for seizure disorder when aged >=3 and after inadequate response/intolerance to generic gabapentin.

Horizant (gabapentin ER): Managed under pharmacy benefit; may be considered medically necessary for neuropathic pain when ALL are met: the individual is aged 18 years or older AND has tried and had an inadequate response or intolerance to generic gabapentin AND has tried and had an inadequate response or intolerance to one of: a tricyclic antidepressant (e.g., amitriptyline) or an SNRI (e.g., duloxetine, venlafaxine) AND has tried and had an inadequate response or intolerance to generic pregabalin or generic pregabalin extended-release. For restless legs syndrome, may be considered medically necessary when the individual is aged >=18 AND has tried and had an inadequate response or intolerance to ALL of: generic gabapentin AND (generic pregabalin OR generic pregabalin extended-release) AND generic ropinirole OR pramipexole.age >=18

step therapy requires multiple trials

Lyrica (pregabalin): Managed under pharmacy benefit; may be considered medically necessary for neuropathic pain when ALL are met: the individual is aged 18 years or older AND has tried and had an inadequate response or intolerance to generic gabapentin AND has tried and had an inadequate response or intolerance to one of: a tricyclic antidepressant (e.g., amitriptyline) or an SNRI (e.g., duloxetine, venlafaxine) AND has tried and had an inadequate response or intolerance to generic pregabalin or generic pregabalin extended-release. For seizure disorder: the individual is aged 1 month or older AND has tried and had an inadequate response or intolerance to generic pregabalin or generic pregabalin extended-release. For fibromyalgia: the individual is aged 18 years or older AND has tried and had an inadequate response or intolerance to generic gabapentin AND has tried and had an inadequate response or intolerance to two of: a TCA, an SNRI, cyclobenzaprine, or tramadol AND has tried and had an inadequate response or intolerance to generic pregabalin or generic pregabalin extended-release.age varies by indication

multiple agent-specific branches

Neurontin (gabapentin): Managed under pharmacy benefit; may be considered medically necessary for neuropathic pain when ALL are met: the individual is aged 18 years or older AND has tried and had an inadequate response or intolerance to generic gabapentin AND has tried and had an inadequate response or intolerance to generic pregabalin or generic pregabalin extended-release.age >=18

document prior trials

Qutenza (capsaicin 8% patch): Managed under medical benefit; may be considered medically necessary for diabetic peripheral neuropathy or postherpetic neuralgia when ALL are met: the individual is aged 18 years or older AND has tried and had an inadequate response or intolerance to generic gabapentin.age >=18

HCPCS J7336 applies

Savella (milnacipran): Managed under pharmacy benefit; may be considered medically necessary for fibromyalgia when ALL are met: the individual is aged 18 years or older AND has tried and had an inadequate response or intolerance to one of: gabapentin, pregabalin, or pregabalin extended-release AND has tried and had an inadequate response or intolerance to two of: a tricyclic antidepressant (e.g., amitriptyline) or an SNRI (e.g., duloxetine, venlafaxine).age >=18

step therapy required

Tonmya (cyclobenzaprine sublingual): Managed under pharmacy benefit; may be considered medically necessary for fibromyalgia when ALL are met: the individual is aged 18 years or older AND has tried and had an inadequate response or intolerance to one of: gabapentin, pregabalin, or pregabalin extended-release AND has tried and had an inadequate response or intolerance to two of: a tricyclic antidepressant (e.g., amitriptyline) or an SNRI (e.g., duloxetine, venlafaxine).age >=18

step therapy required

Evidence summaries by agent

Clinical evidence summaries and relative positioning of agents:

Duloxetine (Cymbalta): Short-term (12-week) randomized trials and a 52-week safety study show duloxetine 60-120 mg QD reduces 24-hour average pain and increases ≥30% responders in diabetic peripheral neuropathy; 60 mg/day is effective with no clear added benefit at higher doses and higher doses are less well tolerated. Duloxetine also showed efficacy in short-duration fibromyalgia trials (60–120 mg/day).60 mg/day effective

Data limited by short trial durations

Milnacipran (Savella): Milnacipran demonstrated efficacy versus placebo at 3 months for fibromyalgia; 6-month data are less consistent. Safety concerns include elevated blood pressure, heart rate, and LFTs; not recommended in patients with liver dysfunction, substantial alcohol use, or uncontrolled blood pressure or heart rate.3 months efficacy

No head-to-head trials vs other FM agents

Pregabalin (Lyrica):

Recent coverage criteria updates

Selected policy coverage updates and requirements (documented changes in this portion of the policy history):

Qutenza coverage: Coverage criteria for Qutenza (capsaicin) were added for treatment of postherpetic neuralgia and diabetic peripheral neuropathy, effective July 4, 2024.effective July 4, 2024

HCPCS code J7336 was added to the policy

Non-formulary exception authorization duration: Non-formulary exception review authorizations for all drugs listed in this policy may be approved up to 12 months.<= 12 months

Clarified in 03/01/25 history entry

Generic prerequisite requirement: As of the 01/01/25 update, prerequisite medications required by coverage criteria must be a generic dosage form.generic dosage form required

Except as specifically allowed under the agent-specific coverage criteria, all other uses of the drugs listed in this policy for the approved conditions are considered not medically necessary. Coverage is limited to indications and situations that meet the drug-specific criteria described in this policy and supported by documentation submitted with the prior authorization request.

Savella (milnacipran) is indicated for fibromyalgia and showed superiority to placebo at 3 months, though longer-term data are less consistent. Milnacipran is not recommended in individuals with liver dysfunction, substantial alcohol use, or uncontrolled blood pressure or heart rate because of safety concerns (including elevated blood pressure, heart rate, and liver function test abnormalities). Clinicians should consider these risks and review prescribing information when evaluating milnacipran for fibromyalgia.

Certain gabapentin products were reorganized across related policies and their coverage criteria updated. For several branded gabapentin formulations (including gabapentin extended‑release, Gralise, Gabarone, and Horizant) the policy now generally requires the individual be aged ≥18 years and to have documented inadequate response or intolerance to prior trials specified by product (for neuropathic pain typically trials of generic gabapentin and pregabalin or pregabalin extended‑release, and a tricyclic antidepressant or an SNRI). See the product-specific criteria for age limits and required prior trials.

Drugs and formulations that do not meet the specific, drug‑level coverage criteria outlined in this policy are not medically necessary for the conditions addressed by the policy. Requests that lack required prior trials, age criteria, or supporting documentation will not meet medical necessity unless they satisfy the explicit exceptions documented in the policy.

A 2018 literature update that included Cochrane meta-analyses concluded that the quality of evidence supporting use of SNRIs in fibromyalgia remained low to very low. The review also found little evidence supporting combination drug therapy across multiple classes and did not support the use of cannabidiol. These findings informed the policy’s conservative stance on combination pharmacotherapy for fibromyalgia.

A 2022 literature and label review identified no new information that would change the policy’s coverage criteria for pregabalin or milnacipran. As part of the 2022 update, prior authorization was removed for generic pregabalin and generic pregabalin extended‑release, reflecting operational changes in authorization status for those generics.

Coding and Billing

HCPCSHCPCSCovered

J7336

Capsaicin 8% patch (Qutenza), per sq cm

HCPCS (policy note)HCPCS

J7336

Capsaicin 8% patch (Qutenza), per sq cm — listed for billing and prior authorization purposes

Added HCPCS CodesHCPCS

J7336

Qutenza (capsaicin) HCPCS code added to policy

Age requirement for certain gabapentin products (inv-12)

Age requirement>= 18 years for specified gabapentin products (e.g., generic gabapentin extended release, Gralise, Gabarone, Horizant)

Indication contextRequirement applies to management of neuropathic pain and to RLS indication for Horizant as specified

Prior trials requiredMust have tried generic gabapentin and pregabalin (or pregabalin ER) plus a TCA or SNRI per product-specific criteria

Prior Authorization, Documentation, and Step Therapy

Prior Authorization

Prior Authorization Required

Prior authorization is required for the listed branded agents and certain medical-benefit products; approvals may be granted up to 12 months. Non-formulary exception reviews and all other reviews for drugs in this policy may be approved for up to 12 months if coverage criteria are met and chart notes show continued positive clinical response.

Approval length: up to 12 months for initial authorization and re-authorization when criteria met and documentation shows clinical benefit.

Documentation Required

Documentation Required for Prior Authorization

Documentation in the form of chart notes and medical records must be provided with the prior authorization review. Lack of adequate documentation (e.g., absence of chart notes showing trials, dates, dosing, or response) may result in denial of the request.

Documentation requirement: provide medical records/chart notes demonstrating prior trials, intolerances or inadequate responses, and ongoing clinical benefit.

Clinical Background

Neuropathy refers to dysfunction of one or more peripheral nerves and commonly produces sensory disturbances such as pain, numbness, tingling, burning, or electric‑shock sensations. Fibromyalgia is a chronic pain disorder characterized by widespread musculoskeletal pain, tender points, fatigue, and altered central pain processing. Both neuropathic pain and fibromyalgia can substantially impair function and quality of life and are frequent reasons for pharmacologic management described in this policy.

Definitions and Key Terms

Neuropathy — definition and common symptom descriptors (inv-26)

DefinitionProblems with one or more nerves that may cause loss of feeling, numbness, tingling, or pain

Common symptom descriptorsNeuropathic pain often described as electric shock, burning, or knifing; may include extreme sensitivity to touch, numbness, or tingling

Clinical relevanceIncluded as a primary target condition for multiple agents in this policy

Fibromyalgia — concise definition and pathophysiology (inv-27)

DefinitionA long-term condition causing widespread muscle and bone pain, tender points, and fatigue

Conceptual pathophysiologyThought to result from changes in how the brain and spinal cord process pain signals (altered central pain processing)

Policy Summary

PayerPremera Bluecross

PolicyPharmacologic Treatment of Neuropathy, Fibromyalgia, and Seizure Disorders

Policy CodePolicy N/A

Change TypeCoverage criteria added and prior authorization updates

Effective DateNov. 1, 2025 Oct. 14, 2025 N/A

Next Review DateN/A

Key ActionSubmit prior authorization with chart notes/medical records documenting required trials of listed generic medications and intolerance or inadequate response when seeking coverage.

SourceLink

On This Page

Pregabalin has modest efficacy versus placebo for neuropathic pain and fibromyalgia with responder definitions typically ≥30% pain reduction; greatest observed relief was at 450 mg/day with no additional benefit at 600 mg/day. Adverse events include dizziness and nausea; pediatric fibromyalgia trial (ages 12–17) did not meet the primary endpoint.

450 mg/day maximal observed benefit

Generic pregabalin prior authorization status changed across updates

Tramadol: Two randomized trials demonstrated tramadol efficacy in diabetic peripheral neuropathy at doses up to 400 mg/day; tramadol has SNRI properties and an opioid metabolite and is often used in combination strategies.<=400 mg/day

Combination therapy often more effective than single agent

Opioid analgesics: Long-acting oxycodone showed benefit in PHN and DPN trials at specified doses (up to 60 mg/day in PHN and up to 120 mg/day in DPN) but utility is limited by the risk of opioid dependence.oxycodone CR up to 60–120 mg/day

Consider dependence risk

Qutenza (capsaicin patch): Two 12-week randomized, dose-controlled trials in postherpetic neuralgia showed a greater reduction in average pain at Week 8 for a single 60-minute application of Qutenza (with topical anesthetic pretreatment) compared with low-dose control; concomitant stable pain medications were allowed and pain diaries were used for outcome measurement.single 60-minute application

Pivotal trials enrolled PHN ≥6 months post-rash with baseline NPRS 3–9

Applies to all listed prerequisite medication trials

Gabapentin product requirements: History entries on 09/01/25 and 11/01/25 updated coverage for gabapentin products (generic gabapentin extended release, Gralise, Gabarone, Horizant) to require the individual be aged >=18, have tried generic gabapentin and generic pregabalin or pregabalin extended-release, and a TCA or SNRI; Gabarone criteria were expanded to include seizure disorder and Horizant RLS criteria were specified.age >=18; prior trials required

See history entries for specific effective dates and policy transfers

Documentation Required

Trial Documentation Practices

Providers must document how trials of comparator therapies were conducted. For topical products (e.g., Qutenza), clinical trials required stable concomitant pain medications, use of topical anesthetic prior to application, and pain diaries were used — include similar details when available (trial duration, stability of concomitant meds, pain diary entries, and application notes).

Trial-use documentation practices: include duration of trial, stability of concomitant medications, pain diary entries, and any topical trial details.
Qutenza trial notes: topical anesthetic used prior to application; patients recorded pain daily in a diary.

Step Therapy

Step Therapy — Trial of Generics Required

Step therapy: many branded agents require documented trials of specified generic alternatives and evidence of inadequate response or intolerance before approval. The policy specifies trial of generic dosage forms as the prerequisite medication tried.

Step requirement: documented trial of generics (generic gabapentin, generic pregabalin or generic pregabalin extended-release, or generic SNRIs) with inadequate response or intolerance.
Policy clarifies prerequisite medication must be a generic dosage form (updated 01/01/25).

Prior Authorization

Pregabalin Prior Authorization and Step Requirements

Pregabalin (Lyrica) and pregabalin extended-release: policy updates over time required use of generic pregabalin or generic pregabalin extended-release first for many indications, but in 2022 prior authorization for the generic pregabalin products was removed. When prior authorization is required for Lyrica or branded pregabalin formulations, providers must show trial and inadequate response or intolerance to the specified generic pregabalin option(s) where the PA remains in effect.

2021: required use of generic pregabalin or generic pregabalin extended-release first.
2022: removed prior authorization for generic pregabalin and generic pregabalin extended-release (PA no longer required for those generics).
When PA applies to branded pregabalin, document trial and inadequate response/intolerance to the generic pregabalin option(s).

Billing Rule

Prior Authorization and Billing

Prior authorization and billing: certain medical-benefit products require PA and specific HCPCS coding. Qutenza (capsaicin 8% patch) is billed using HCPCS J7336 (per sq cm) — include appropriate code on claims and ensure PA documentation supports medical-necessity criteria.

HCPCS J7336: Capsaicin 8% patch (Qutenza), per sq cm.
Ensure PA includes documentation of prior trials (e.g., generic gabapentin) and clinical notes supporting use for postherpetic neuralgia or diabetic peripheral neuropathy.

Note

Trial of Generic Alternatives

Trial of generic alternatives: multiple products in this policy explicitly require trials of listed generic medications (for example, generic gabapentin, generic pregabalin or pregabalin extended-release, a tricyclic antidepressant, or a generic SNRI) before branded or non-preferred agents will be considered medically necessary.

2014 update: policy required generic SNRI trial as a qualifier for coverage.
Examples of required generics: gabapentin, pregabalin or pregabalin ER, tricyclic antidepressants (e.g., amitriptyline), and SNRIs (e.g., duloxetine, venlafaxine).

Denial Risk

Provider Actions — Documentation and Denial Risk

Provider actions: failure to submit chart notes/medical records documenting prior trials, dates, dosing, reasons for discontinuation (intolerance or inadequate response), and ongoing benefit may result in denial. Include all relevant documentation with the PA submission.

Explicit denial risk if documentation is lacking with PA review.
Include supporting records at time of PA submission to avoid delays or denials.

Clinical featuresOften presents with diffuse musculoskeletal pain, tenderness to touch, and functional impact such as fatigue

Seizure disorders — brief definition (inv-28)

DefinitionConditions caused by unusual electrical activity in the brain leading to seizures

Clinical implicationSome agents in this policy are indicated for seizure disorders as well as neuropathic pain

SymptomsUncontrolled electrical signals produce seizures and related neurologic manifestations

Conditions discussed in policy (inv-29)

Conditions referencedPostherpetic neuralgia (PHN)

Conditions referencedDiabetic peripheral neuropathy (DPN)

Conditions referencedFibromyalgia (FM)

Qutenza (capsaicin) — topical product and coverage (inv-30)

ProductQutenza (capsaicin 8% patch) — topical capsaicin product added to policy

Covered indicationsMay be considered medically necessary for postherpetic neuralgia (PHN) and diabetic peripheral neuropathy (DPN) when criteria met

Key trial detailsEfficacy established in two 12-week randomized, dose-controlled trials using a single 60-minute application with topical anesthetic pre-treatment

Generic pregabalin — PA history and role (inv-31)

HistoryGeneric pregabalin and pregabalin extended-release were removed from prior authorization in 2022 (PA no longer required)

Programmatic roleWhen prior authorization was required for branded agents, generic pregabalin and pregabalin ER were referenced as required first-line generic options prior to branded use

Subsequent referencesLater policy updates continued to reference generic pregabalin as a prerequisite option in step therapy language when PA applied to branded formulations